Innovent prepares to file GLP-1/glucagon agonist mazdutide in China for diabetes, its second indication after obesity.

For Lilly, orforglipron could also complement its injectable formulation of tirzepatide for diabetes – Mounjaro – and injectable GLP-1 agonist Trulicity (dulaglutide).